论文部分内容阅读
目的研究硝普钠与西地兰治疗急性左心衰竭患者中的有效性和安全性。方法选取医院心内科住院急性左心衰竭病患者56例,随机分为硝普钠组与西地兰组各28例。2组在常规治疗基础上分别予硝普钠及西地兰治疗,比较2组患者血压、心率、症状缓解时间、不良反应等。结果 2组患者血压和心率情况均得到良好控制,硝普钠组控制情况优于西地兰组,差异有统计学意义(P<0.05)。2种药物对急性左心衰竭治疗均具良好效果(有效率>90%);硝普钠组心力衰竭症状缓解所需时间更短,起效更快,差异有统计学意义(P<0.05)。2组治疗后均未出现心律失常、血压下降过快、休克等不良反应。结论硝普钠与西地兰治疗急性左心衰竭均有明显效果,安全性较高;硝普钠对比西地兰在治疗效果、起效时间上具有优势。
Objective To study the efficacy and safety of sodium nitroprusside and cedilanid in patients with acute left heart failure. Methods 56 cases of hospitalized patients with acute left heart failure in cardiology department were randomly divided into sodium nitroprusside group and cedilanid group of 28 cases. Two groups were treated with sodium nitroprusside and cedilanid respectively on the basis of routine treatment. The blood pressure, heart rate, symptom relief time and adverse reactions in two groups were compared. Results The blood pressure and heart rate were well controlled in both groups. The control in sodium nitroprusside group was better than that in cedilanid group (P <0.05). Both drugs had good effect on the treatment of acute left heart failure (effective rate> 90%); the sodium nitroprusside group had shorter remission time and faster onset of symptoms, the difference was statistically significant (P <0.05) . No arrhythmia, rapid decline in blood pressure, shock and other adverse reactions occurred in both groups after treatment. Conclusion Sodium nitroprusside and cedilanid are effective and safe in the treatment of acute left heart failure. Sodium nitroprusside is superior to cedilanid in treatment effect and onset time.